Patents Assigned to Ospedale San Raffaele S.r.L.
-
Publication number: 20220031765Abstract: The present invention relates to the field of bacterial strain to be used in medicine. In particular, it relates to the prevention and/or treatment of cancer or diabetes, bacterial strain is Prevotella melaninogenica.Type: ApplicationFiled: December 2, 2019Publication date: February 3, 2022Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Matteo Maria Salvatore BELLONE, Arianna BREVI, Arianna CALCINOTTO, Roberto FERRARESE, Filippo CANDUCCI
-
Publication number: 20210290646Abstract: The present invention relates to at least one glycosylation inhibitor for use in combination with CAR cell therapy. Preferably, the glycosylation inhibitor improves the therapeutic potential of the CAR cell therapy. The invention also relates to a pharmaceutical composition and to population or subpopulation of CAR cell that has been contacted with at least one glycosylation inhibitor.Type: ApplicationFiled: July 22, 2019Publication date: September 23, 2021Applicants: OSPEDALE SAN RAFFAELE S.R.L., FONDAZIONE CENTRO SAN RAFFAELEInventors: Attilio BONDANZA, Monica CASUCCI, Beatrice GRECO
-
Publication number: 20210277354Abstract: The present disclosure relates to a genetically modified dendritic cell or precursor thereof expressing at least one anti-gen-derived peptide and at least one immuno-modulatory molecule, its medical use and method of preparation. The invention also relates to an in vitro method to produce IL-10-producing CD49b+LAG-3+ Tr1 cells or antigen-specific FOXP3+ T cells and relative medical uses and pharmaceutical compositions.Type: ApplicationFiled: June 19, 2019Publication date: September 9, 2021Applicants: FONDAZIONE TELETHON, FONDAZIONE CENTRO SAN RAFFAELE, OSPEDALE SAN RAFFAELE S.R.L.Inventors: Andrea ANNONI, Silvia Adriana GREGORI
-
Publication number: 20210276967Abstract: The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.Type: ApplicationFiled: July 19, 2019Publication date: September 9, 2021Applicants: OSPEDALE SAN RAFFAELE S.R.L., IRBM S.P.A., PROMIDIS S.R.L., ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGMInventors: Raffaele DE FRANCESCO, Adolfo PRANDI, Pietro RANDAZZO, Lorena DONNICI, Luca GUIDOTTI, Matteo IANNACONE, Romano DI FABIO, Vincenzo SUMMA, Leda Ivanova BENCHEVA, Marilenia DE MATTEO, Luca FERRANTE
-
Publication number: 20210252275Abstract: The present invention relates to a method for early detection of artificial pump dysfunction based on a time-frequency analysis of the pump motor power consumption (PRC). The method allows to prevent low output syndrome, cardiogenic shock, pump thrombus and/or cardiac arrest or death as well as to monitor the efficacy of a thrombolytic therapy and/or to optimize intensity and duration of a thrombolytic therapy.Type: ApplicationFiled: September 13, 2019Publication date: August 19, 2021Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Federico ESPOSTI, Filippo CONSOLO, Federico Severine PAPPALARDO
-
Patent number: 10940236Abstract: A synthetic composite material for tissue repair is disclosed which includes a first layer having an organic material and having side walls and external surface; and a second porous layer comprising an inorganic material and having side walls; wherein the first layer is in direct contact with the second layer and wherein the side walls of the first layer and the side walls of the second layer are coated with a third layer of the organic material.Type: GrantFiled: May 19, 2014Date of Patent: March 9, 2021Assignees: OSPEDALE SAN RAFFAELE S.R.L., UNIVERSITÀ DEL SALENTOInventors: Giuseppe Peretti, Gianfranco Fraschini, Alessandro Sannino, Francesca Gervaso, Francesco Scalera, Alessia Di Giancamillo, Cinzia Domeneghini, Daniela Rosa Deponti
-
Publication number: 20210046159Abstract: The present invention relates to a IL-1 antagonist alone or in combination with other therapeutic agents and relative pharmaceutical compositions for use for the treatment and/or prevention of toxicity induced by a T cell therapy, wherein the T cell expresses at least one recombinant receptor.Type: ApplicationFiled: March 8, 2019Publication date: February 18, 2021Applicants: OSPEDALE SAN RAFFAELE S.R.L., FONDAZIONE CENTRO SAN RAFFAELEInventors: Attilio BONDANZA, Barbara CAMISA, Margherita NORELLI
-
Patent number: 10912824Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.Type: GrantFiled: July 13, 2015Date of Patent: February 9, 2021Assignees: Ospedale San Raffaele S.r.l., Fondazione TelethonInventors: Alessio Cantore, Angelo Leone Lombardo, Luigi Naldini
-
Publication number: 20210015834Abstract: The invention relates to compounds, in particular NK-1 antagonists, for use in the treatment of ocular sensitivity and/or ocular pain.Type: ApplicationFiled: February 26, 2019Publication date: January 21, 2021Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Paolo RAMA, Giulio FERRARI
-
Publication number: 20200278356Abstract: The invention features compositions and methods for the treatment and prevention of peroxisomal diseases (e.g., neonatal adrenoleukodystrophy and Zellweger syndrome), including in a subject selected as having increased levels of metallothionein polypeptides. The invention also provides compositions and methods for identifying a subject having a peroxisomal disease involving detecting metallothionein polypeptides or polynucleotdies.Type: ApplicationFiled: January 16, 2018Publication date: September 3, 2020Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., DANA-FARBER CANCER INSTITUTE, INC.Inventors: ALESSANDRA BIFFI, ELEONORA CAVALCA
-
Publication number: 20200182870Abstract: Use of (i) an anti-CD3 antibody, (ii) an anti-CD56 antibody, (iii) an anti-CD14 antibody, (iv) an anti-CD38 antibody, (v) an anti-CD45 antibody, (vi) an anti-CD90 antibody, (vii) an anti-CD135 antibody, (viii) an anti-CD10 antibody, (ix) an anti-CD11c antibody, (x) an anti-CD19 antibody, (xi) an anti-CD34 antibody, (xii) an anti-CD45RA antibody, (xiii) an anti-CD7 antibody, (xiv) an anti-CD71 antibody, (xv) an anti-CD41/CD61 complex antibody or an anti-CD41 antibody and/or an anti-CD61 antibody (xvi) an anti-CD33 antibody and/or an anti-CD66b antibody, for identifying hematopoietic cell subtypes in an isolated sample, determining the relative frequency of hematopoietic cell subtypes in an isolated sample and/or quantifying the number of cells within hematopoietic cell subtypes in an isolated sample, wherein each of (i) to (xvi) is labelled with a different fluorochrome, wherein when (xvi) is an anti-CD33 antibody and an anti-CD66b antibody, the anti-CD33 antibody and anti-CD66b are labelled with the same fluoType: ApplicationFiled: October 17, 2017Publication date: June 11, 2020Applicants: Ospedale San Raffaele S.r.l., Fondazione TelethonInventors: Luca BASSO-RICCI, Luca BIASCO, Alessandro AIUTI
-
Patent number: 10626153Abstract: The present invention relates to HMGB1 variants that maintain HMGB1 wild type chemoattractant function while displaying abolished cytokine and/or chemokine stimulating properties. Such molecules are useful in therapy.Type: GrantFiled: July 26, 2013Date of Patent: April 21, 2020Assignee: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Marco Emilio Bianchi, Maura Casalgrandi, Emilie Joelle Venereau, Silvia Brunelli
-
Patent number: 10617721Abstract: A method of preparing a therapeutic cell population for clinical use from a starting population of cells comprising haematopoietic stem cells, said method comprising separating a population of cells that substantially do not express CD38 but which express CD34 from the starting population of cells, and transducing the separated cell population with a vector to obtain the therapeutic cell population.Type: GrantFiled: October 24, 2014Date of Patent: April 14, 2020Assignees: OSPEDALE SAN RAFFAELE S.R.L., FONDAZIONE TELETHONInventors: Luigi Naldini, Bernhard Rudolf Gentner, Erika Zonari, Francesco Boccalatte
-
Publication number: 20200087630Abstract: Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. The inventors provide the first evidence of a causal link between influenza virus infection and the development of type 1 diabetes and/or pancreatitis. This causal link between infection and type 1 diabetes and/or pancreatitis provides various therapeutic, prophylactic and diagnostic opportunities.Type: ApplicationFiled: July 25, 2019Publication date: March 19, 2020Applicants: Ospedale San Raffaele S.r.l., Istituto Zooprofilattico Sperimentale delle VenezieInventors: Lorenzo Piemonti, Ilaria Capua
-
Publication number: 20200038439Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.Type: ApplicationFiled: October 16, 2017Publication date: February 6, 2020Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHONInventors: ALESSANDRA BIFFI, MARCO PEVIANI, DAVIDE MOSCATELLI, ALESSIA CAPATANDO, RITA MILAZZO, UMBERTO CAPASSO PALMIERO
-
Publication number: 20190367584Abstract: The present invention provides compositions and methods for the treatment or prevention of a lysosomal disease or disorder involving increasing the level, expression, or activity of a metallothionein polypeptide or polynucleotide in the subject.Type: ApplicationFiled: January 16, 2018Publication date: December 5, 2019Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., DANA-FARBER CANCER INSTITUTE, INC.Inventors: ALESSANDRA BIFFI, ELEONORA CAVALCA
-
Publication number: 20190211307Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.Type: ApplicationFiled: February 28, 2019Publication date: July 11, 2019Applicants: Yale University, Ospedale San Raffaele S.r.l, Fondazione TelethonInventors: Richard A. FLAVELL, Nicola GAGLIANI, Silvia GREGORI, Samuel HUBER, Chiara Francesca MAGNANI, Maria Grazia RONCAROLO
-
Patent number: 10287579Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.Type: GrantFiled: April 30, 2010Date of Patent: May 14, 2019Assignees: Ospedale San Raffaele S.r.l., Fondazione TelethonInventors: Alessandra Biffi, Bernhard Rudolf Gentner, Luigi Naldini
-
Patent number: 10260042Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.Type: GrantFiled: September 21, 2017Date of Patent: April 16, 2019Assignees: Yale University, Ospedale San Raffaele S.r.l., Fondazione TelethonInventors: Richard A. Flavell, Nicola Gagliani, Silvia Gregori, Samuel Huber, Chiara Francesca Magnani, Maria Grazia Roncarolo
-
Publication number: 20180273912Abstract: Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. The inventors provide the first evidence of a causal link between influenza virus infection and the development of type 1 diabetes and/or pancreatitis. This causal link between infection and type 1 diabetes and/or pancreatitis provides various therapeutic, prophylactic and diagnostic opportunities.Type: ApplicationFiled: January 5, 2018Publication date: September 27, 2018Applicants: Ospedale San Raffaele S.r.l., Istituto Zooprofilattico Sperimentale delle VenezieInventors: Lorenzo PIEMONTI, Ilaria CAPUA